ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ BỆNH NHÂN COVID-19 NẶNG CẦN HỖ TRỢ OXY DÒNG CAO QUA CANUYL MŨI (HFNC)

Abstract

Using High-flow nasal cannula (HFNC) in severe COVID-19 patients helps to reduce the rate of invasive mechanical ventilation and mortality. Objectives: To describe clinical and laboratory manifestations as well as mortality among severe COVID-19 patients using HFNC. Methods: This was a retrospective study collecting and analyzing data of COVID-19 patients using HFNC from April, 2021 to December, 2023 in National Hospital for Tropical Diseases, Vietnam. Results: The average age was 65 ± 16.4 years old in which patients aged 61-80 was predominant. 71.1% patient had underlying diseases that hypertension (43.4%) and diabetes (25.3%) were the most common. The rate of success was 41%. Fever (57.5%) and dyspnea (88%) was the most common clinical symptoms. 71.1% patients suffered elevated D-dimer. 95% patients have lung damage on chest CT, mainly both lungs. At time T2, the breathing rate in the failure group was higher significant than the success group (p<0.05). SpO2, PaO2, and PaO2/FiO2 in the failure group were lower than the success group (p<0.05). The duration using HFNC in the success group was longer than the failure group. Conclusion: HFNC therapy showed an improvement in terms of clinical symptoms and blood oxygenation deficiency.